FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...

Wojciech Jurczak, MD, PhD, ​​discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase ...

Wojciech Jurczak, MD, PhD, discusses advancements in B-cell lymphoma therapy, focusing on immunotherapy, molecular-targeted agents, and more.

Last November, results from the MITIGATE trial made headlines at ACR Convergence 2024 with positive phase 3 trial data for inebilizumab, an IgG1 monoclonal antibody targeting CD19, in patients with ...

The Johns Hopkins T-cell and Cutaneous Lymphoma Program provides expertise in all forms of systemic peripheral T-cell lymphomas and cutaneous T-cell lymphomas, including mycosis fungoides and others.

Distinguishing TMM from primary cutaneous neoplasms may be challenging and is often dependent on the identification of an adjacent conventional melanoma. In particularly difficult cases, molecular ...

Lymphoma is a type of cancer that begins in immune system cells, called lymphocytes. It generally presents as a solid tumor of lymphoid cells and can develop in the lymph nodes, spleen, bone ...

We compared obinutuzumab, a humanised type II anti-CD20 monoclonal antibody that induces potent B-cell ... in the primary endpoint of complete renal response, subsequent analyses suggested that the ...

This study focused solely on booster vaccinations and did not evaluate the safety of the primary MMR series ... Uziel Y, Moshe V, Onozo B, et al. Live attenuated MMR/V booster vaccines in children ...